Shares of Moderna rocketed by 93% to around $121.90 on Wednesday, pacing what would be the stock’s best-ever trading session after surging by more than 100% in premarket trading. That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of skin cancer—in a late-stage trial involving more than 1,

Moderna stock surged on Phase 3 mRNA cancer vaccine results with Merck, breaking key moving averages and hitting record RSI.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 175% in the previous session on positive clinical trial news.

Moderna declines after skyrocketing the previous session. Walmart falls as guidance fails to impress.

Even with a modest 25% success rate for the company's current phase 2 programs, Moderna should be able to launch enough new products over the next five years to improve its financial results. So, the stock remains a buy, at least for investors willing to hold onto Moderna's shares for at least five years.

Moderna has been looking for its next blockbuster drug after a wildly successful COVID era.

Many Fed officials favor raising rates to combat inflation, bond prices surge, Trump meets crypto execs, and more news to start your day.

Moderna MRNA stock fell 20%% to $138, compared with Wednesday’s close of $174.38. The decline followed a more than doubling of the shares on August 19 after Moderna and Merck announced positive results from the Phase 3 INTerpath-001 study of their personalized mRNA cancer vaccine, intismeran autogene.